Our findings are in line with a prior report from a Japanese series [18] where a non-significant increase of neutropenia incidence was also observed in patients carrying the UGT1A1*6/*28 heterozygous genotype, despite initially reduced irinotecan doses. This evidence concerns the gene UGT1A1 and neutropenia.